22 results about "Macrophage polarization" patented technology

The application discloses a degradable polymer-based bone repair 3D printing composite material and a preparation method and application thereof, and belongs to the technical field of bone repair material preparation.The raw material of the degradable polymer-based bone repair 3D printing composite material comprises a degradable polymer, a compatibilizer and hydroxyapatite and Mg(OH)2 co-loaded chitosan microspheres.The degradable polymer-based bone repair 3D printing composite material has good mechanical properties, biocompatibility, mineralization capacity, antibacterial and anti-inflammatory properties, can be used as a bone repair material, and is used for preparing a bone repair product through 3D printing after being prepared into a bone repair 3D printing wire material through extrusion molding, thereby providing a novel material solution for bone tissue regeneration and repair.The chitosan can adjust macrophage polarization and reduce the expression of inflammatory factors, so that the composite material has anti-inflammatory properties.

This invention belongs to the field of biomedical materials technology, specifically disclosing a core-shell microneedle, a core-shell microneedle patch, its preparation method, and its application. Through structural design and carrier material optimization, this invention provides a core-shell microneedle with a programmed sequential release of tannic acid in the outer shell and verteporfen in the core layer, successfully matching the dynamic physiological rhythm of wound healing and ensuring effective wound repair. In vitro and in vivo biological evaluations have confirmed that the core-shell microneedle patch prepared using the core-shell microneedles of this invention possesses excellent antibacterial, antioxidant, and immune microenvironment-regulating abilities. It can effectively induce macrophage polarization towards the M2 type, specifically inhibit YAP protein expression, and significantly accelerate the closure process of infected wounds. From both upstream immune regulation and downstream fibrosis inhibition levels, it dually blocks the pathological scar formation pathway, ultimately achieving high-quality, scar-free regenerative repair of infected wounds.

This invention provides a pH-responsive immunomodulatory microneedle patch, its preparation method, and its application, belonging to the field of biomedical materials technology. This invention incorporates Zif-8 nanoparticles loaded with ChABC into GelMA hydrogel to prepare a pH-responsive immunomodulatory microneedle patch (Z@C-MN). As the patch gradually degrades, the system can continuously release Zn in a pH-responsive manner. 2+ Z@C-MN, along with ChABC, promotes in situ repair of cerebral fibrosis (SCI) after injury. Z@C-MN induces macrophage polarization towards a pro-regenerative phenotype, thereby downregulating the inflammatory response, increasing neurite length, and promoting the differentiation of neural stem cells into neurons. In vivo, Z@C-MN reduced the inflammatory microenvironment after injury and promoted angiogenesis in a rat SCI model. Furthermore, it activated axonal regeneration by inhibiting scar tissue formation and regulating CD4+. + T cell transformation supports neurogenesis.

This invention relates to the field of medical materials technology, providing a hydrogel containing antler mesenchymal stem cell exosomes, its preparation method, and applications. The method includes the following steps: preparation of antler mesenchymal stem cell exosomes; preparation of PVP-HA composite hydrogel; uniformly mixing AMSC-Exos with a hydrogel precursor solution, and forming a hydrogel containing antler mesenchymal stem cell exosomes through physical embedding and non-covalent interactions. This invention utilizes the three-dimensional porous network structure of the hydrogel to achieve long-term sustained release of exosomes, protecting them from rapid degradation; it leverages the unique regenerative advantages of antler-derived exosomes to synergistically promote angiogenesis, inhibit inflammatory responses, and regulate macrophage polarization; it promotes angiogenesis through the miR-486-5p / FGF9 axis, achieving efficient repair of chronic diabetic wounds; and it provides a novel, efficient, safe, and clinically translational strategy for the treatment of chronic diabetic skin lesions.

This invention discloses a composite scaffold for promoting bone regeneration in diabetic patients, its preparation method, and its applications, relating to the field of medical biomaterials technology. The composite scaffold for promoting bone regeneration in diabetic patients comprises: a three-dimensional porous framework; and a bioactive hydrogel layer loaded with naringin. The bioactive hydrogel layer loaded with naringin is coated on the surface and pore walls of the three-dimensional porous framework. The technical solution provided by this invention uses a 3D-printed PLGA / HA porous framework to provide mechanical support and osteoconductivity, and a supramolecular hydrogel coating loaded with naringin to endow it with immunomodulatory and drug sustained-release functions. This scaffold has good hydrophilicity and biocompatibility, and can effectively induce macrophage polarization towards the M2 anti-inflammatory phenotype by activating the JAK-STAT signaling pathway, improving the local inflammatory microenvironment of diabetic bone defects. Simultaneously, it indirectly promotes vascular endothelial cell migration, lumen formation, and osteogenic differentiation of bone marrow mesenchymal stem cells by regulating macrophages.

The application discloses the technical field of carbon dot application, and relates to a luteolin carbon dot for guiding lysosomes and a preparation method and application thereof. The luteolin carbon dot is prepared by using luteolin and 2,5-dihydroxyterephthalic acid as carbon source precursors through a hydrothermal method. The prepared luteolin carbon dot has a particle size of 0.5-4 nm, a fluorescence excitation wavelength of 360-440 nm, a maximum emission wavelength of 540 nm and a Zeta potential of -19 mv. Research shows that the luteolin carbon dot can guide macrophage and adipocyte lysosomes, promote M2 type macrophage polarization, and up-regulate the expression of the heat production and brown colorization marker gene Ucp1 of beige adipocytes. Further, the M2 type macrophage loaded with the luteolin carbon dot can promote the expression of the Ucp1 of the beige adipocyte through the release of the carbon dot and the paracrine effect, thereby increasing heat production and energy consumption. The application lays a foundation for developing an intervention and treatment scheme for obesity and related metabolic diseases based on the carbon dot in the future.

This invention belongs to the field of biomedical technology, specifically disclosing the application of cimicifuga in the preparation of drugs for treating periodontitis. Specifically, it relates to the application of cimicifuga in the preparation of drugs for treating periodontitis; and the application of cimicifuga in the preparation of drugs for treating alveolar bone defects (periodontal bone defects) caused by periodontitis. It also relates to the application of cimicifuga in the preparation of products for inhibiting macrophage polarization towards M1 and / or promoting macrophage polarization towards M2 in a single macrophage system. In this disclosure, cimicifuga has no significant toxicity to macrophages and has high safety; it targets and regulates macrophage polarization, inhibiting periodontal inflammation at its source; it significantly reduces inflammatory infiltration and osteoclast formation in periodontal tissues, effectively alleviating alveolar bone defects; and it provides a novel targeted immunotherapy drug for periodontitis, expanding the clinical application of single traditional Chinese medicine monomers.

This invention provides a peptide targeting graft-versus-host disease, its expression system, and a local in-situ regulatory system, belonging to the field of biomedical technology. This invention also provides the application of the peptide BigLEN in the preparation of macrophage pyroptosis inhibitors. BigLEN has a high affinity for the NLRP3 NACHT domain, and in vitro experiments have confirmed its effective inhibition of NLRP3-mediated pyroptosis in macrophages. This invention constructs a fusion protein and expression vector based on arabinose-induced expression, and an arabinose-inducible engineered EcN strain. Oral administration significantly improves survival rate, reduces intestinal pathological damage, decreases the infiltration of pro-inflammatory T cells, and promotes macrophage polarization towards an anti-inflammatory phenotype. This invention develops an orally administered engineered probiotic to precisely inhibit NLRP3-driven pyroptosis in intestinal macrophages.

This invention relates to the field of cardiovascular disease research technology, and particularly to the application of the NOD1 inhibitor ML130 in hypoxia-induced macrophage polarization, including the use of ML130 in the preparation of drugs that regulate hypoxia-induced macrophage polarization. These drugs inhibit the NOD1 / RIP2 signaling axis and can be used to intervene in the formation and progression of atherosclerotic plaques. This invention creatively combines the NOD1 inhibitor ML130 with the hypoxic microenvironment of atherosclerotic plaques, specifically inhibiting the NOD1 / RIP2 signaling pathway and directly regulating macrophage polarization balance; reducing the accumulation of pro-inflammatory cells in unstable plaque areas, inhibiting foam cell formation and necrotic core expansion, significantly improving plaque stability, and reducing the risk of serious cardiovascular events such as acute coronary syndrome; it clarifies that ML130 exerts its effect by blocking the NOD1 / RIP2-NF-κB / MAPK signaling axis, exhibiting high target specificity and avoiding the side effects of broad-spectrum inhibition by traditional anti-inflammatory drugs.

This invention relates to the application of stem cell exosomes in drugs for treating ulcerative colitis. The stem cell exosomes include antler stem cell-derived exosomes (ASC-exo) and human umbilical cord mesenchymal stem cell-derived exosomes (HucMSC-exo). The drugs used in this invention can promote the proliferation and migration of NCM460 colonic epithelial cells and reduce apoptosis; they can regulate macrophage polarization, shifting it from M1 to M2 polarization; in vivo experiments, they alleviate DSS-induced weight loss, reduced food intake, and shortened colon length in mice, improve disease activity index, and effectively reduce pathological changes observed in ulcerative colitis models, providing new insights for drug development in inflammatory bowel disease.

The application discloses a kind of polydopamine-coated inulin-chitosan composite microspheres loaded with garlic exosomes and a preparation method and application thereof, the composite microspheres are formed by Schiff base reaction of aldehyde inactivated inulin and chitosan to form hydrogel framework, embedding garlic-derived exosome-like nanoparticles inside, and coating polydopamine layer on the surface.The application is prepared by microfluidic electrospray technology, and the obtained microspheres have uniform particle size, controllable structure and good biocompatibility.The composite microspheres are stable in gastric juice, degrade responsively in colon environment and release exosomes, and the polydopamine layer enhances intestinal mucosa adhesion and retention.The microspheres have anti-inflammatory, antioxidant, macrophage polarization regulation, intestinal barrier repair and intestinal flora regulation functions, and can be used for preparing drugs or oral preparations for preventing or treating inflammatory bowel disease (especially colitis).

The application discloses application of a recombinant MBL2 protein in preparation of a medicine for treating metabolic disorder associated liver disease (MAFLD), wherein the amino acid sequence of the recombinant MBL2 protein is shown as SEQ ID NO. 1, or is an active variant or fragment with at least 95% homology and retaining natural immune regulation and metabolic regulation functions. The application provides a brand-new drug action target and treatment mechanism, and fills the blank of MAFLD specific therapy. MAFLD is the result of multiple attacks, and single-pathway drugs often have poor effects. The recombinant MBL2 protein provided by the application has multiple biological functions: it can remove damage signals through the phagocytosis function of macrophages, reduce inflammation through the regulation of macrophage polarization, and improve insulin resistance and promote lipid metabolism through the activation of the AMPK pathway in the liver.

This invention belongs to the field of medical material preparation technology, and discloses a ternary synergistic self-assembled hydrogel with dual functions of microwave sensitization and immunomodulation, its preparation method, and applications. The hydrogel uses arginine, glycyrrhizic acid, and α-lipoic acid as the sole building blocks, and is prepared in a one-step method via thermally induced ring-opening polymerization and electrostatic self-assembly. Arginine not only acts as a natural solubilizer for LA, but its guanidinocation also forms a stable electrostatic interaction with the carboxyl anion of GA / LA, constituting a three-dimensional network. It can function as a highly efficient microwave sensitizer, precisely raising the local temperature of tumors to a mild thermotherapy window of 50-55°C under low-power microwave irradiation, achieving effective ablation; it can also function as an immunomodulator, significantly promoting dendritic cell maturation and M1 macrophage polarization, reshaping the immunosuppressive microenvironment. Furthermore, it exhibits excellent injectability, self-healing properties, shear-thinning properties, and biocompatibility.

The application belongs to the field of biological medicine, and provides application of TGF-beta / Smad signal pathway in treatment of corneal neovascularization after corneal alkali burn. The application proves that by inhibiting the TGF-beta / Smad signal pathway, the alkali burn-induced corneal neovascularization can be significantly reduced, and the corneal pathological damage is improved, and the mechanism of action involves regulating M2 type macrophage polarization and inhibiting the process of cellular ferroptosis of corneal tissue. It is found that by using a specific inhibitor SB-431542, the expression of TGF-beta1 and p-Smad2 / 3 proteins can be effectively reduced, the angiogenic factors such as VEGFA and CD31 are reduced, the inflammatory factors such as IL-4 and IL-10 are down-regulated, the GSH level is restored, and the Fe 2+ and MDA contents are reduced. The application is suitable for developing a targeted therapeutic drug for pathological neovascularization after corneal alkali burn, and provides a theoretical basis.

This invention belongs to the field of biomedical materials and tissue engineering technology, and provides a decellularized matrix composite hydrogel dressing, its preparation method, and its application. The decellularized matrix composite hydrogel dressing provided by this invention includes a hydrogel matrix and ginger exosome-like nanoparticles (GELNs) dispersed in the hydrogel matrix; the hydrogel matrix is ​​prepared from raw materials including decellularized dermal matrix and decellularized aortic adventitia matrix. The composite hydrogel dressing of this invention has a three-dimensional porous structure, enabling sustained release of GELNs. It also significantly accelerates the healing process of full-thickness skin defects by downregulating the TLR4 / MyD88 / NF-κB signaling pathway, synergistically regulating macrophage polarization towards the M2 type, and simultaneously promoting angiogenesis and collagen deposition. The dressing has widely available raw materials, good biocompatibility, and broad application prospects in the field of skin wound repair.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and discloses a TCM composition for treating ulcerative colitis, its preparation method, and its uses. The TCM composition comprises the following raw materials in parts by weight: 2-10 parts of charred Typhae Pollen, 3-7 parts of charred Scutellariae Radix, 4-6 parts of charred Angelicae Sinensis Radix, 3-8 parts of charred Sophorae Fructus, 6-10 parts of Prunus Mume, 2-10 parts of prepared Zingiberis Rhizoma, 5-7 parts of prepared Aconitum Carmichaelii Radix, 3-7 parts of Coptise Rhizoma, and 1-8 parts of Indigo Naturalis Radix. Among these, Prunus Mume is the principal ingredient, with prepared Zingiberis Rhizoma and prepared Aconitum Carmichaelii Radix as assistant ingredients, and charred Angelicae Sinensis Radix, charred Sophorae Fructus, charred Typhae Pollen, charred Scutellariae Radix, Coptise Rhizoma, and Indigo Naturalis as adjuvants. The synergistic effect among the various TCM components gives the TCM composition of this invention the effects of soothing the liver and strengthening the spleen, astringing the intestines and stopping bleeding. It is mainly used to treat moderate to severe ulcerative colitis. Experiments have demonstrated that the traditional Chinese medicine composition of this invention can inhibit intestinal inflammatory response in mice with ulcerative colitis; improve pathological histological damage and promote intestinal mucosal repair; regulate macrophage polarization and restore the balance of M1 / M2 macrophages; regulate CD4+ T cell differentiation and reshape Th17 / Treg cell immune homeostasis.

This invention relates to effective and safe compositions comprising anionic gold-polydopamine core-shell nanoworms as alternative gene vectors to overcome endosome escape bottlenecks. The nanoworms can be used in methods for delivering therapeutic oligonucleotides to subjects. A polydopamine shell supports surface-adsorbed nucleic acids. Nanoworms encapsulating anionic nucleic acids can then enter cells without transfection agents and activate ClC3H in late endosomes. + / Cl ‑ Ion exchangers, to mediate H + and Cl ‑ Nanoworms accumulate within vesicles, leading to membrane rupture and ultimately escaping into the cytosol without cell-penetrating peptides or mechanical stimulation. Nanoworms can also be used for cell programming (i.e., primary macrophage polarization and stem cell differentiation) and for treating diseases (such as renal fibrosis and acute liver injury).

This invention discloses the application of sodium copper chlorophyllin in the preparation of drugs for treating osteoarthritis, belonging to the field of biomedical technology. The sodium copper chlorophyllin of this invention can block excessive activation of osteoclasts and subsequent angiogenesis, and successfully reprograms macrophage polarization, exhibiting significant anti-inflammatory and repairing effects. Furthermore, this invention constructs a dual-targeted sustained-release drug delivery system. After encapsulating sodium copper chlorophyllin into MOF material, the MOF material is then modified with MMP9 responsive peptides and bone-targeting peptides via click chemistry, achieving the goal of continuously releasing sodium copper chlorophyllin to the subchondral bone region of osteoarthritis.

This invention discloses a pH / ROS-responsive multifunctional hydrogel loaded with ruthenium dioxide nanoparticles, its preparation method, and its applications. Belonging to the field of biomedical materials and drug delivery technology, it utilizes Schiff base reactions and dynamic borate ester reactions to load RuNPs and form a hydrogel (G@Ru) to address several key factors: i) RuNPs exhibit inherent antibacterial activity and ROS scavenging, alleviating inflammation and promoting tissue regeneration, thus accelerating the healing of MRSA-infected diabetic wounds; ii) A ROS / pH dual-responsive hydrogel matrix (Gel) is synthesized as a smart drug carrier, intelligently releasing RuNPs using the pH-responsive activity of the Schiff base and the ROS-responsive activity of the dynamic borate ester; iii) RuNPs reduce inflammation levels while regulating macrophage polarization, promoting angiogenesis and cell proliferation; iv) G@Ru accelerates tissue remodeling and repair through collagen deposition, achieving faster recovery with minimal scarring.

This invention relates to the field of cardiovascular diseases and discloses the application of miRNA-454 in the treatment of atherosclerosis. This invention is the first to discover that hsa-miRNA-454-3p can bind to the 3'UTR region of IRF1 mRNA, inhibiting IRF1 expression, thereby suppressing the IRF1-NF-κB pathway and M1 macrophage polarization, promoting M2 macrophage polarization, and simultaneously restoring macrophage phagocytic capacity. This dual regulation reduces plaque inflammation, promotes the clearance of apoptotic debris from lesions, and ultimately slows down atherosclerosis.

This invention relates to the field of biomedical materials technology, specifically to a composite microsphere material for sequentially regulating macrophage polarization and its preparation method. The material employs a core-shell structure design, with a core layer of GELMA hydrogel containing WKYMVm short peptides and a shell layer of a composite material of graphene oxide and PVA. The preparation method includes: preparing core and shell solutions, preparing W / O emulsion droplets using microfluidic technology, UV photocrosslinking, washing and purification, and shell coating. This material can promote M1-type macrophage polarization to clear necrotic tissue in the early stages of bone repair through graphene oxide. As the shell hydrogel degrades, the WKYMVm short peptides are gradually released, promoting M2-type macrophage polarization to inhibit inflammation, promote angiogenesis, and facilitate bone repair. This invention achieves precise temporal regulation of macrophage polarization, exhibits good biocompatibility and biodegradability, and has a simple and controllable preparation process, showing broad application prospects in the field of bone defect repair.

The application discloses a kind of recombinant biomimetic polypeptide nanomaterial for precision regulation and control macrophage polarization and application thereof, and relates to the field of bioengineering.The recombinant biomimetic polypeptide capable of self-assembling into nanofiber is prepared, and the recombinant biomimetic polypeptide material is self-assembled, which can specifically activate macrophages, make them polarize into M1 type, and the polarized macrophages have killing effect on tumor cells, so as to be expected to be applied to tumor immunotherapy.